1076 related articles for article (PubMed ID: 26969258)
1. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
Marty FM; Ostrosky-Zeichner L; Cornely OA; Mullane KM; Perfect JR; Thompson GR; Alangaden GJ; Brown JM; Fredricks DN; Heinz WJ; Herbrecht R; Klimko N; Klyasova G; Maertens JA; Melinkeri SR; Oren I; Pappas PG; Ráčil Z; Rahav G; Santos R; Schwartz S; Vehreschild JJ; Young JH; Chetchotisakd P; Jaruratanasirikul S; Kanj SS; Engelhardt M; Kaufhold A; Ito M; Lee M; Sasse C; Maher RM; Zeiher B; Vehreschild MJGT;
Lancet Infect Dis; 2016 Jul; 16(7):828-837. PubMed ID: 26969258
[TBL] [Abstract][Full Text] [Related]
2. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
[TBL] [Abstract][Full Text] [Related]
3. Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.
Shirley M; Scott LJ
Drugs; 2016 Nov; 76(17):1647-1657. PubMed ID: 27766566
[TBL] [Abstract][Full Text] [Related]
4. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
Miceli MH; Kauffman CA
Clin Infect Dis; 2015 Nov; 61(10):1558-65. PubMed ID: 26179012
[TBL] [Abstract][Full Text] [Related]
5. Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.
Ledoux MP; Denis J; Nivoix Y; Herbrecht R
J Mycol Med; 2018 Mar; 28(1):15-22. PubMed ID: 29551442
[TBL] [Abstract][Full Text] [Related]
6. Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.
Kovanda LL; Marty FM; Maertens J; Desai AV; Lademacher C; Engelhardt M; Lu Q; Hope WW
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289034
[TBL] [Abstract][Full Text] [Related]
7. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.
Marty FM; Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Oren I; Schmitt-Hoffmann AH; Giladi M; Rahav G; Perfect JR
Mycoses; 2018 Jul; 61(7):485-497. PubMed ID: 29611227
[TBL] [Abstract][Full Text] [Related]
8. Isavuconazonium: first global approval.
McCormack PL
Drugs; 2015 May; 75(7):817-22. PubMed ID: 25902926
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.
Jenks JD; Salzer HJ; Prattes J; Krause R; Buchheidt D; Hoenigl M
Drug Des Devel Ther; 2018; 12():1033-1044. PubMed ID: 29750016
[TBL] [Abstract][Full Text] [Related]
11. Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.
Rybak JM; Marx KR; Nishimoto AT; Rogers PD
Pharmacotherapy; 2015 Nov; 35(11):1037-51. PubMed ID: 26598096
[TBL] [Abstract][Full Text] [Related]
12. Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study).
Kovanda LL; Desai AV; Lu Q; Townsend RW; Akhtar S; Bonate P; Hope WW
Antimicrob Agents Chemother; 2016 Aug; 60(8):4568-76. PubMed ID: 27185799
[TBL] [Abstract][Full Text] [Related]
13. Isavuconazole: a new extended spectrum triazole for invasive mold diseases.
Ananda-Rajah MR; Kontoyiannis D
Future Microbiol; 2015; 10(5):693-708. PubMed ID: 26000646
[TBL] [Abstract][Full Text] [Related]
14. Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.
Kovanda LL; Maher R; Hope WW
Expert Rev Clin Pharmacol; 2016 Jul; 9(7):887-97. PubMed ID: 27160418
[TBL] [Abstract][Full Text] [Related]
15. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.
Riley TT; Muzny CA; Swiatlo E; Legendre DP
Ann Pharmacother; 2016 Sep; 50(9):747-57. PubMed ID: 27307416
[TBL] [Abstract][Full Text] [Related]
16. Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial.
Perfect JR; Cornely OA; Heep M; Ostrosky-Zeichner L; Mullane KM; Maher R; Croos-Dabrera R; Lademacher C; Engelhardt M; Chen C; Marty FM
Mycoses; 2018 Jul; 61(7):420-429. PubMed ID: 29570857
[TBL] [Abstract][Full Text] [Related]
17. Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report.
Cornu M; Bruno B; Loridant S; Navarin P; François N; Lanternier F; Amzallag-Bellenger E; Dubos F; Mazingue F; Sendid B
BMC Pharmacol Toxicol; 2018 Dec; 19(1):81. PubMed ID: 30522521
[TBL] [Abstract][Full Text] [Related]
18. Isavuconazonium sulfate for the treatment of fungal infection.
Walker RC; Zeuli JD; Temesgen Z
Drugs Today (Barc); 2016 Jan; 52(1):7-16. PubMed ID: 26937491
[TBL] [Abstract][Full Text] [Related]
19. Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): A multicentre, non-interventional registry study.
Thompson GR; Garcia-Diaz J; Miceli MH; Nguyen MH; Ostrosky-Zeichner L; Young JH; Fisher CE; Clark NM; Greenberg RN; Spec A; Kovanda L; Croos-Dabrera R; Kontoyiannis DP
Mycoses; 2022 Feb; 65(2):186-198. PubMed ID: 34888961
[TBL] [Abstract][Full Text] [Related]
20. Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.
Gebremariam T; Wiederhold NP; Alqarihi A; Uppuluri P; Azie N; Edwards JE; Ibrahim AS
J Antimicrob Chemother; 2017 Feb; 72(2):462-466. PubMed ID: 27798213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
